Alembic Pharmaceuticals Ltd

Alembic Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Pharmaceuticals Ltd

₹ 962 -0.62%
21 May - close price
alembic-india.com BSE: 533573 NSE: APLLTD
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company[1] Alembic is among the top 25 players in domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5% in the domestic market.

Website BSE NSE
  • Market Cap ₹ 18,869 Cr.
  • Current Price ₹ 962
  • High / Low ₹ 1,304 / 725
  • Stock P/E 33.0
  • Book Value ₹ 264
  • Dividend Yield 1.14 %
  • ROCE 13.1 %
  • ROE 11.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 39.4%

Cons

  • Stock is trading at 3.64 times its book value
  • The company has delivered a poor sales growth of 7.69% over past five years.
  • Company has a low return on equity of 10.6% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
1,416 1,262 1,475 1,509 1,406 1,486 1,595 1,631 1,517 1,562 1,648 1,693 1,770
1,268 1,255 1,244 1,274 1,203 1,287 1,387 1,364 1,257 1,325 1,409 1,433 1,498
Operating Profit 148 7 231 235 204 199 208 266 260 237 239 260 271
OPM % 10% 1% 16% 16% 14% 13% 13% 16% 17% 15% 15% 15% 15%
10 1 0 0 1 12 10 3 4 2 30 10 14
Interest 7 9 12 15 14 14 16 15 11 13 19 22 25
Depreciation 123 67 68 67 74 66 68 69 69 69 71 70 69
Profit before tax 29 -67 151 154 116 130 135 185 183 157 180 178 192
Tax % 24% -2% 12% 21% -31% 7% -1% 2% 3% 14% 15% 23% 18%
22 -66 133 122 153 121 137 180 178 135 153 138 157
EPS in Rs 1.12 -3.35 6.78 6.20 7.76 6.14 6.95 9.18 9.07 6.85 7.80 7.04 7.98
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,863 2,056 3,166 3,105 3,131 3,935 4,606 5,393 5,306 5,653 6,229 6,672
1,506 1,653 2,159 2,490 2,488 3,061 3,383 3,913 4,432 4,970 5,296 5,664
Operating Profit 358 403 1,007 615 643 874 1,223 1,480 874 682 932 1,008
OPM % 19% 20% 32% 20% 21% 22% 27% 27% 16% 12% 15% 15%
4 4 7 2 7 9 -39 87 56 -2 28 56
Interest 10 4 5 5 3 18 27 16 18 50 56 79
Depreciation 40 44 72 83 105 115 157 183 287 275 273 279
Profit before tax 311 359 936 529 541 749 1,000 1,368 625 355 632 707
Tax % 24% 21% 23% 23% 22% 21% 20% 19% 17% 4% 3% 18%
236 283 720 403 413 583 801 1,146 521 342 616 582
EPS in Rs 12.49 15.01 38.20 21.39 21.89 31.00 43.97 58.33 26.50 17.40 31.33 29.68
Dividend Payout % 24% 23% 9% 19% 18% 18% 23% 24% 38% 46% 35% 37%
Compounded Sales Growth
10 Years: 12%
5 Years: 8%
3 Years: 8%
TTM: 7%
Compounded Profit Growth
10 Years: 7%
5 Years: -7%
3 Years: 3%
TTM: -7%
Stock Price CAGR
10 Years: 6%
5 Years: 1%
3 Years: 8%
1 Year: 1%
Return on Equity
10 Years: 18%
5 Years: 13%
3 Years: 11%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 38 38 38 38 38 38 38 39 39 39 39 39
Reserves 638 847 1,560 1,865 2,182 2,681 3,182 5,028 5,198 4,331 4,779 5,152
109 264 114 89 708 1,128 1,747 584 717 722 513 1,258
432 493 718 698 1,013 931 1,022 1,058 1,167 1,090 1,114 1,324
Total Liabilities 1,217 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446 7,773
397 547 708 799 993 1,158 1,552 1,788 1,798 2,398 2,547 2,524
CWIP 21 83 93 396 1,010 1,551 1,846 2,183 2,304 601 524 837
Investments 3 2 87 50 42 49 18 236 118 96 93 127
796 1,009 1,541 1,444 1,896 2,019 2,573 2,502 2,902 3,087 3,281 4,285
Total Assets 1,217 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446 7,773

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
240 172 948 329 312 812 449 1,463 552 724 803 88
-81 -256 -307 -486 -884 -756 -731 -840 -372 -448 -321 -568
-151 87 -224 -129 503 59 155 -597 -217 -262 -438 444
Net Cash Flow 8 3 417 -286 -69 115 -127 26 -37 14 45 -37

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 54 64 40 40 61 45 69 24 56 68 60 77
Inventory Days 159 196 266 269 302 356 417 431 406 315 350 466
Days Payable 148 166 264 213 313 237 220 194 178 145 157 179
Cash Conversion Cycle 65 94 42 96 51 164 266 261 283 237 253 363
Working Capital Days 50 71 49 72 93 64 118 94 118 119 114 153
ROCE % 44% 38% 66% 29% 22% 23% 24% 26% 11% 7% 13% 13%

Shareholding Pattern

Numbers in percentages

9 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.67%
5.94% 5.32% 4.99% 4.55% 4.34% 4.51% 4.52% 4.46% 4.32% 3.94% 4.17% 3.94%
12.15% 12.55% 12.76% 13.32% 13.65% 14.22% 14.51% 15.39% 15.47% 16.05% 16.05% 16.43%
12.30% 12.52% 12.64% 12.53% 12.39% 11.67% 11.36% 10.54% 10.61% 10.38% 10.17% 9.96%
No. of Shareholders 1,01,4571,03,8111,01,86499,52297,60789,55285,21276,56774,82991,42993,94491,336

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls